Gepant Adverse Events Chart
Posted on August 15 2024,
| Adverse Event Category | Rimegepant (Nurtec ODT) | Atogepant (Qulipta) | Ubrogepant (Ubrelvy) |
|---|---|---|---|
| Gastrointestinal (Stomach and digestive system) | - Highest severity of nausea - Moderate incidence of constipation - Reports of abdominal pain |
- Most frequent overall gastrointestinal issues - Highest prominence of constipation - Reports of decreased appetite |
- Less prominent than others - Some reports of nausea and vomiting - Occasional abdominal discomfort |
| Skin and Subcutaneous Tissue | - Most frequent rash and pruritus (itching) - Highest severity of alopecia (hair loss) - Reports of urticaria (hives) |
- Secondary severity of alopecia - Some reports of rash and pruritus - Occasional skin hypersensitivity (increased skin sensitivity) |
- Less prominent than others - Few reports of rash and pruritus - Rare cases of angioedema |
| Cardiac | - Strongest overall cardiac adverse events signal - Reports of palpitations - Some cases of chest discomfort |
- Strong signals for cardiac flutter (irregular heartbeat) - Reports of tachycardia (rapid heart rate) - Some cases of hypertension |
- Comparable rates to others - Occasional reports of chest pain - Few cases of bradycardia (slow heart rate) |
| Musculoskeletal and Connective Tissue | - Less prominent than others - Some reports of myalgia (muscle pain) - Occasional arthralgia (joint pain) |
- Moderate reports of back pain - Some cases of muscle spasms - Occasional reports of joint stiffness |
- Most positive signals for skeletal muscle adverse events - Increased signals for muscle tightness and neck pain - Reports of muscle weakness |
| Raynaud's Phenomenon (Poor blood flow to fingers and toes) | - Strongest signal - More frequent reports of cold extremities - Cases of color changes in fingers/toes |
- Secondary signal strength - Some reports of tingling in extremities - Occasional numbness in fingers/toes |
- Least prominent - Rare reports of Raynaud's-like symptoms - Few cases of sensitivity to cold |
| Hepatobiliary (Liver-related) | - Scarce reports across all three gepants - Severe AEs detected in clinical trials, not in post-marketing data - Occasional reports of elevated liver enzymes (indicators of liver stress) - Rare cases of jaundice (yellowing of skin/eyes) reported - Continued monitoring recommended for all gepants |
||
Data source: VigiAccess and FDA Adverse Event Reporting System (FAERS) databases up to March 31, 2024.
Note: This chart summarizes key findings and does not represent a comprehensive list of all adverse events. The frequency and severity of adverse events may vary among individuals.
Sat, Apr 19, 25
FDA Authorizes First Digital Therapeutic for Migraine
In a development for migraine patients, the FDA has granted marketing authorization to CT-132, making it the first prescription digital therapeutic specifically designed for the preventive treatment of episodic migraine...
Read MoreFri, Apr 18, 25
Weather Conditions & Migraine Attacks: Is there a relationship?
This meta-analysis found that weather conditions, especially temperature and ambient pressure changes as well as increased levels of certain air pollutants (PM10, PM2.5, NO2, CO, and O3), are significantly associated...
Read MoreFri, Apr 18, 25